GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Kanion Pharmaceutical Co Ltd (SHSE:600557) » Definitions » YoY EBITDA Growth

Jiangsu Kanion Pharmaceutical Co (SHSE:600557) YoY EBITDA Growth : -31.67% (As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Jiangsu Kanion Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Jiangsu Kanion Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -31.67%.

Jiangsu Kanion Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2025 was ¥0.19.


Jiangsu Kanion Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for Jiangsu Kanion Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Kanion Pharmaceutical Co YoY EBITDA Growth Chart

Jiangsu Kanion Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.65 15.14 19.57 0.73 -4.96

Jiangsu Kanion Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.81 -5.65 -16.98 -34.21 -31.67

Jiangsu Kanion Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Jiangsu Kanion Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(1.053-1.108)/ | 1.108 |
=-4.96 %

Jiangsu Kanion Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(0.192-0.281)/ | 0.281 |
=-31.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Kanion Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Jiangsu Kanion Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Kanion Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 58 Haichang South Road, Xinpu District, Jiangsu, Lianyungang, CHN, 222001
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
Executives
Pan Yu Director
Wang Chuan Lei Director
Yang Yong Chun Director
Liu Quan Director
Wang Zhen Zhong Director
Chen Xue Bin Director
Xu Dian Hong Director
Wu Yun Director
Gao Hai Xin Director
Xiao Wei Director
Wan Yan Huan senior management
Xia Yue Director
Yang Yin Director

Jiangsu Kanion Pharmaceutical Co Headlines

No Headlines